ZA915466B - A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose - Google Patents

A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose

Info

Publication number
ZA915466B
ZA915466B ZA915466A ZA915466A ZA915466B ZA 915466 B ZA915466 B ZA 915466B ZA 915466 A ZA915466 A ZA 915466A ZA 915466 A ZA915466 A ZA 915466A ZA 915466 B ZA915466 B ZA 915466B
Authority
ZA
South Africa
Prior art keywords
flupirtine
agent
preparation
active substance
muscular tension
Prior art date
Application number
ZA915466A
Other languages
English (en)
Inventor
Michael Lobisch
Lobisch Michael
Bernd Nickel
Nickel Bernd
Jurgen Engel
Engel Jurgen
Ralph Venhaus
Venhaus Ralph
Istvan Szelenyi
Szelenyi Istvan
Peter Emig
Emig Peter
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of ZA915466B publication Critical patent/ZA915466B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Paints Or Removers (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA915466A 1990-07-14 1991-07-12 A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose ZA915466B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (cs) 1990-07-14 1991-06-04

Publications (1)

Publication Number Publication Date
ZA915466B true ZA915466B (en) 1992-04-29

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA915466A ZA915466B (en) 1990-07-14 1991-07-12 A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose

Country Status (30)

Country Link
US (2) US5162346A (cs)
EP (2) EP0659410B1 (cs)
KR (1) KR0182811B1 (cs)
CN (1) CN1070700C (cs)
AT (2) ATE206919T1 (cs)
AU (1) AU634073B2 (cs)
CA (1) CA2046943C (cs)
CZ (1) CZ280879B6 (cs)
DE (3) DE59109222D1 (cs)
DK (2) DK0467164T3 (cs)
EG (1) EG19814A (cs)
ES (2) ES2164111T3 (cs)
GR (1) GR3019179T3 (cs)
HR (1) HRP920667B1 (cs)
HU (1) HU206973B (cs)
IE (1) IE74688B1 (cs)
IL (1) IL98810A (cs)
IN (1) IN172468B (cs)
LT (1) LT3593B (cs)
LV (1) LV10048B (cs)
MC (1) MC2272A1 (cs)
MX (1) MX9100160A (cs)
NO (1) NO912758L (cs)
NZ (1) NZ238940A (cs)
PT (1) PT98291B (cs)
RO (1) RO108220B1 (cs)
RU (1) RU2070408C1 (cs)
SI (1) SI9111227B (cs)
SK (1) SK279567B6 (cs)
ZA (1) ZA915466B (cs)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9321574U1 (de) * 1992-03-11 2000-06-29 Asta Medica Ag, 01277 Dresden Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
HRP20020192A2 (en) * 1999-08-03 2004-02-29 Awd Pharma Gmbh & Co Kg Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
EP2012769A1 (en) * 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
EP2061465B1 (en) * 2006-08-23 2013-04-10 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) * 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
EA201070189A1 (ru) * 2007-08-01 2010-08-30 Х. Лундбекк А/С Применение соединений, открывающих калиевые каналы kcnq, для подавления симптомов или лечения расстройств или состояний, при которых нарушается дофаминергическая система
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
TW202128162A (zh) 2019-11-08 2021-08-01 加拿大商再諾製藥公司 憂鬱症之治療方法
JP2024508660A (ja) 2021-02-09 2024-02-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
EP0189788B1 (de) * 1985-01-23 1989-09-13 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika
DE3663775D1 (en) * 1985-02-23 1989-07-13 Asta Pharma Ag Combination of flupirtin with spasmolytics having an anticholinergic effect
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A7 (fi) * 1985-06-28 1986-12-29 Degussa Flupirtiinin ja 4-asetamido-fenolin synergistinen yhdistelmä.

Also Published As

Publication number Publication date
HUT59313A (en) 1992-05-28
EP0467164A3 (en) 1992-04-15
LV10048B (en) 1995-06-20
LV10048A (lv) 1994-05-10
ATE133564T1 (de) 1996-02-15
PT98291A (pt) 1992-05-29
ES2164111T3 (es) 2002-02-16
US5284861A (en) 1994-02-08
CN1070700C (zh) 2001-09-12
IL98810A (en) 1996-01-19
ATE206919T1 (de) 2001-11-15
PT98291B (pt) 1999-01-29
MC2272A1 (fr) 1993-06-23
EP0659410A3 (de) 1995-10-25
SI9111227A (en) 1995-06-30
SI9111227B (sl) 2000-12-31
KR0182811B1 (ko) 1999-05-01
EP0467164A2 (de) 1992-01-22
US5162346A (en) 1992-11-10
EG19814A (en) 1996-02-29
DK0467164T3 (da) 1996-03-04
CA2046943A1 (en) 1992-01-15
IE74688B1 (en) 1997-07-30
DE59107331D1 (de) 1996-03-14
CZ280879B6 (cs) 1996-04-17
CA2046943C (en) 1996-03-12
CN1058716A (zh) 1992-02-19
NO912758L (no) 1992-01-15
IE912451A1 (en) 1992-01-15
AU634073B2 (en) 1993-02-11
DK0659410T3 (da) 2001-12-27
MX9100160A (es) 1992-02-28
ES2082887T3 (es) 1996-04-01
EP0659410B1 (de) 2001-10-17
EP0659410A2 (de) 1995-06-28
NZ238940A (en) 1997-05-26
LT3593B (en) 1995-12-27
GR3019179T3 (en) 1996-06-30
HU206973B (en) 1993-03-01
RU2070408C1 (ru) 1996-12-20
HRP920667A2 (en) 1996-10-31
DE4122166A1 (de) 1992-01-16
SK279567B6 (sk) 1999-01-11
AU8040391A (en) 1992-01-16
EP0467164B1 (de) 1996-01-31
LTIP919A (en) 1995-03-27
IN172468B (cs) 1993-08-14
RO108220B1 (ro) 1994-03-31
HU912359D0 (en) 1991-12-30
HRP920667B1 (en) 1998-06-30
CS210191A3 (en) 1992-02-19
DE59109222D1 (de) 2001-11-22
KR920002147A (ko) 1992-02-28
IL98810A0 (en) 1992-07-15
NO912758D0 (no) 1991-07-12

Similar Documents

Publication Publication Date Title
ZA915466B (en) A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
EP0331620A3 (en) Agent for the treatment of parkinson's disease
GR3030269T3 (en) Use of il-10 to prevent or treat insulin-dependent diabetes mellitus.
MY104521A (en) Treatment of depression.
EP0872246A4 (en) INNOVATIVE MEDICINE TO REDUCE PAIN AND PROMOTE REMOVAL OF CONCRETE IN UROLITHIASIS
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
GR3029726T3 (en) Use of a therapeutic compound for the treatment of bronchitis
KR920009403A (ko) 수면장해 치료용 이미다조벤조디아제핀
GR3002925T3 (en) Compound active in cardiovascular therapy
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
IL82279A0 (en) Fumigant method and compositions comprising 2,2-dibromo-3-nitrilopropionamide for treating crops
FR2714058B1 (fr) Dérivés de 1,3-dioxane trisubstitués, leur préparation et leur application en thérapeutique.
GEP19971009B (en) Flupirtine in combination with antiparkinsonica against muscle bracing
BG98001U (en) Medicament for the treatment of hyperkeratotic conditions of the skin
JPS55141413A (en) Analgesic and muscle stiffness relaxing medicine